A Novel, Regulated Gene Therapy (NGN-401) Study for Female Children With Rett Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05898620 |
Recruitment Status :
Recruiting
First Posted : June 12, 2023
Last Update Posted : March 13, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Rett Syndrome | Genetic: NGN-401 | Phase 1 Phase 2 |
The study is a phase 1/2, open-label study designed to assess the safety, tolerability, and efficacy of administration of an adeno-associated viral vector serotype 9 (AAV9), using Neurogene's proprietary transgene regulation technology. NGN-401 contains a full-length human MECP2 gene which is designed to express therapeutic levels of the MECP2 protein while avoiding overexpression.
The study treatment will be administered under general anesthesia via intracerebroventricular (ICV) delivery. Each participant will be followed for safety and preliminary efficacy for 5 years after treatment and is expected to enroll in a long-term follow-up study for 10 years.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 16 participants |
Allocation: | Non-Randomized |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1/2, Open-Label Clinical Study to Evaluate Safety, Tolerability, and Efficacy of NGN-401 in Pediatric Subjects With Rett Syndrome |
Actual Study Start Date : | June 13, 2023 |
Estimated Primary Completion Date : | October 2029 |
Estimated Study Completion Date : | October 2029 |
Arm | Intervention/treatment |
---|---|
Experimental: Low Dose
Dose Level 1
|
Genetic: NGN-401
NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene. |
Experimental: High Dose
Dose Level 2
|
Genetic: NGN-401
NGN-401 is a non-replicating, recombinant AAV9 carrying a full length human MECP2 transgene. |
- Incidence of Treatment Emergent Adverse Events (TEAEs) [ Time Frame: 5 years ]Incidence, type, severity, and frequency of TEAEs
- Incidence of Serious Adverse Events (SAEs) [ Time Frame: 5 years ]Incidence, type, severity, and frequency of SAEs
- Incidence of Adverse Events of Special Interest (AESIs) [ Time Frame: 5 years ]Incidence, type, severity, and frequency of AESIs
- Incidence of clinical laboratory abnormalities [ Time Frame: 5 years ]Incidence, type, severity, and frequency of clinical laboratory abnormalities
- Incidence of new physical and neurologic exam abnormalities [ Time Frame: 5 years ]Incidence, type, severity, and frequency of new physical and neurologic exam abnormalities
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 4 Years to 10 Years (Child) |
Sexes Eligible for Study: | Female |
Gender Based Eligibility: | Yes |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Diagnosis of typical Rett syndrome with a documented disease-causing mutation in the methyl-CpG-binding protein 2 (MECP2) gene
- Current anti-epileptic drug regimen has been stable for at least 12 weeks
- Participant and caregiver should reside within a 2-hour drive of the study center for at least 3 months following treatment
- Participant must have never taken trofinetide or have taken trofinetide and discontinued due to tolerability, lack of efficacy, or other reasons. Following NGN-401 dosing, trofinetide may be initiated after a specified time period and with the support of the treating clinician
Exclusion Criteria:
- Normal or near normal hand function
- Has a current clinically significant condition other than Rett syndrome
- Presence of a concomitant medical condition that precludes intracerebroventricular administration, or use of anesthetics needed for study related procedures
- Grossly abnormal psychomotor development in the first 6 months of life
- A history of other genetic disorders or neurological conditions, such as stroke, brain tumor, or autoimmune processes affecting the central nervous system
Other inclusion or exclusion criteria apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05898620
Contact: Contact Center | +1 877-237-5020 | medicalinfo@neurogene.com |
United States, Colorado | |
Children's Hospital Colorado | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact NeurogeneRettStudy@childrenscolorado.org | |
United States, Massachusetts | |
Boston Children's Hospital | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact 617-355-5230 rettresearch@childrens.harvard.edu | |
United States, Texas | |
Texas Children's Hospital | Recruiting |
Houston, Texas, United States, 77030 | |
Contact 832-824-7729 NeurogeneRettStudy@BCM.edu |
Study Director: | Julie Jordan, MD | Neurogene Inc. |
Responsible Party: | Neurogene Inc. |
ClinicalTrials.gov Identifier: | NCT05898620 |
Other Study ID Numbers: |
RTT-200 |
First Posted: | June 12, 2023 Key Record Dates |
Last Update Posted: | March 13, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Typical Rett Syndrome MECP2 Rett Disorder Genetic Diseases, Inborn Genetic Diseases, X-Linked Neurodevelopmental Disorders Neurobehavioral Manifestations |
Neurologic Manifestations Intellectual Disability Nervous System Diseases Heredodegenerative Disorders, Nervous System Pathologic Processes RTT |
Rett Syndrome Syndrome Disease Pathologic Processes Mental Retardation, X-Linked Intellectual Disability |
Neurobehavioral Manifestations Neurologic Manifestations Nervous System Diseases Genetic Diseases, X-Linked Genetic Diseases, Inborn Heredodegenerative Disorders, Nervous System |